Information  X 
Enter a valid email address

Omega Diagnostics Gp (ODX)


Thursday 10 February, 2022

Omega Diagnostics Gp

Speculation regarding a potential fundraise

RNS Number : 3385B
Omega Diagnostics Group PLC
10 February 2022


The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.




("Omega" or the "Company" or the "Group")


Speculation regarding a potential fundraise


Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products , notes today's online speculation and confirms that it has conditional investor support for an equity fundraising at 5p per share and that it is considering undertaking a share placing to raise approximately £5m with an accompanying open offer to raise up to a further £2m.


Any such fundraising would however be conditional upon certain other corporate actions currently being explored by the Group and, accordingly, there is no certainty at this time that any such fundraise will proceed.


A further announcement will be made in due course as necessary.





Omega Diagnostics Group PLC

Jag Grewal, Chief Executive Officer 

via Walbrook PR

Chris Lea, Chief Financial Officer

finnCap Ltd  

Tel: 020 7220 0500

Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance)

Alice Lane/ Charlotte Sutcliffe (ECM)

Walbrook PR Limited

Tel: 020 7933 8780 or [email protected]

Paul McManus

Mob: 07980 541 893

Lianne Applegarth

Mob: 07584 391 303

Sam Allen

Mob: 07502 558 258



About Omega Diagnostics Group PLC

Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 75 countries and specialise in the areas of health and nutrition and global health.



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t